Source comparison
CJC-1295 no DAC & Ipamorelin Men Over 40: Research Protocol Comparison
Peak GH Release (Fold Increase vs Baseline) 2.1× 3.4× 8.2× Combined protocol produces synergistic GH release significantly exceeding additive effect Plasma IGF-1 Elevation (% Increase) 18–28% 22–35% 40–60% Only the combined protocol achieves sustained IGF-1 le
This comparison does not assign a generated winner or score.
- Peak GH Release (Fold Increase vs Baseline)
- 2.1×
- 3.4×
- 8.2×
- Combined protocol produces synergistic GH release significantly exceeding additive effect
- Plasma IGF-1 Elevation (% Increase)
- 18–28%
- 22–35%
- 40–60%
- Only the combined protocol achieves sustained IGF-1 levels comparable to low-dose exogenous GH
- Lean Mass Gain (12–16 weeks)
- 0.8–1.5 kg
- 1.0–2.0 kg
- 1.5–3.0 kg
- Dual-peptide protocol doubles lean mass accrual relative to monotherapy
- Visceral Fat Reduction (12–16 weeks)
- 6–10%
- 8–12%
- 12–18%
- Lipolytic effect scales with total GH exposure; combined protocol produces clinically significant VAT reduction
- Cortisol/Prolactin Elevation
- None
- Ipamorelin's selectivity eliminates the cortisol and prolactin spikes seen with GHRP-2 and GHRP-6
- Injection Frequency
- 1–2×/day
- 2–3×/day
- CJC-1295 no DAC's extended receptor binding reduces Ipamorelin dosing frequency when combined